Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice. Issue 20 (21st July 2017)

• Record Type: Journal Article
• Authors: Yu, Mikyung; Amengual, Jaume; Menon, Arjun; Kamaly, Nazila; Zhou, Felix; Xu, Xiaoding; Saw, Phei Er; Lee, Seung‐Joo; Si, Kevin; Ortega, Carleena Angelica; Choi, Won Il; Lee, In‐Hyun; Bdour, Yazan; Shi, Jinjun; Mahmoudi, Morteza; Jon, Sangyong; Fisher, Edward A.; Farokhzad, Omid C.
• Is Part Of: Advanced healthcare materials. Volume 6:Issue 20(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-07-21
• Subjects: atherosclerosis -- GW3965 -- liver X receptor (LXR) -- nanoparticles -- targeted drug delivery; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.201700313
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: The pharmacological manipulation of liver X receptors (LXRs) has been an attractive therapeutic strategy for atherosclerosis treatment as they control reverse cholesterol transport and inflammatory response. This study presents the development and efficacy of nanoparticles (NPs) incorporating the synthetic LXR agonist GW3965 (GW) in targeting atherosclerotic lesions. Collagen IV (Col IV) targeting ligands are employed to functionalize the NPs to improve targeting to the atherosclerotic plaque, and formulation parameters such as the length of the polyethylene glycol (PEG) coating molecules are systematically optimized. In vitro studies indicate that the GW‐encapsulated NPs upregulate the LXR target genes and downregulate proinflammatory mediator in macrophages. The Col IV‐targeted NPs encapsulating GW (Col IV–GW–NPs) successfully reaches atherosclerotic lesions when administered for 5 weeks to mice with preexisting lesions, substantially reducing macrophage content (≈30%) compared to the PBS group, which is with greater efficacy versus nontargeting NPs encapsulating GW (GW–NPs) (≈18%). In addition, mice administered the Col IV–GW–NPs do not demonstrate increased hepatic lipid biosynthesis or hyperlipidemia during the treatment period, unlike mice injected with the free GW. These findings suggest a new form of LXR‐based therapeutics capable of enhanced delivery of the LXR agonist to atherosclerotic lesions without altering hepatic lipid metabolism. Abstract : A new form of liver X receptor‐based therapeutics based on the nanoparticles (NPs) decorated with collagen IV targeting ligands is generated. The NPs with optimal polyethylene glycol density can successfully reach atherosclerotic lesions and enhance therapeutic efficacy of GW3965 while maintaining hepatic lipid metabolism. This targeted NP system suggests a new modality for combating inflammation in advanced atherosclerosis.